CIRM provides funding across five key areas: Infrastructure, Education, Discovery Research, Translational Research, and Clinical Research. By supporting projects at every stage of development, from initial discovery to clinical trials, CIRM drives progress in regenerative medicine and accelerates innovative therapies to patients.
Check out our portfolio of awards below. Click here to see a list of People We’ve Funded. Click here to see a list of our Funded Institutions.
All CIRM Grants
Search Filters »
| Institution |
Researcher name |
Grant Type |
Grant Title |
Award Value |
| University of California, Davis |
Dr Mehrdad Abedi |
Late Stage Preclinical Projects |
Superior forward-oriented b-globin vector for treating Sickle Cell Disease |
$4,598,398 |
| Stanford University |
Dr. Matthew H Porteus |
Late Stage Preclinical Projects |
Autologous Gene Corrected Sinus Basal Cells to Treat Serious Cystic Fibrosis Sinus Disease |
$6,000,000 |
| University of California, Irvine |
Kyriacos A Athanasiou |
Late Stage Preclinical Projects |
Treatment of the TMJ disc complex |
$6,000,000 |
| Aspera Biomedicines, Inc. |
Catriona Jamieson |
Late Stage Preclinical Projects |
Cancer Stem Cell Interception with Rebecsinib: A First-in-Class ADAR1 Inhibitor |
$3,200,000 |
| University of California, Los Angeles |
Dr. Jerome A. Zack Ph.D. |
Late Stage Preclinical Projects |
Clinical Translation of Autologous Regenerative Pluripotent Stem Cell Therapy for Blindness |
$6,000,000 |
| Kenai Therapeutics |
Howard J Federoff |
Late Stage Preclinical Projects |
Allogeneic iPSC derived Dopaminergic Drug Product for Parkinson’s disease |
$4,000,000 |
| Rampart Bioscience |
Jeffrey Bartlett |
Late Stage Preclinical Projects |
Ex vivo Engineering of Autologous Hematopoietic Stem Cells for the Treatment of Hypophosphatasia |
$3,999,980 |
| Nammi Therapeutics, Inc. |
Dr. David R Stover |
Late Stage Preclinical Projects |
IND-Enabling activities for the masked immunocytokine, QXL138AM |
$3,999,113 |
| Calidi Biotherapeutics, Inc. |
8587949607 Boris Minev |
Late Stage Preclinical Projects |
Allogeneic mesenchymal stem cells loaded with oncolytic virus for cancer treatment |
$3,111,467 |
| Ossium Health, Inc. |
Dr. Brian Johnstone |
Late Stage Preclinical Projects |
Development of OSSM-007, cryopreserved interferon-gamma primed allogeneic MSCs, for treatment of steroid refractory acute graft versus host disease |
$3,457,858 |
| University of California, Davis |
Dr. Joseph S Anderson |
Late Stage Preclinical Projects |
Hematopoetic stem cell gene therapy for the treatment of Tay-Sachs disease |
$4,048,253 |
| Stanford University |
Natalia Gomez-Ospina |
Late Stage Preclinical Projects |
Genome Editing of Autologous Hematopoietic Stem Cells to Treat Severe Mucopolysaccharidosis type 1 (Hurler Syndrome) |
$5,444,353 |
| University of California, San Francisco |
Dr. Karin Lindgren Gaensler |
Late Stage Preclinical Projects |
Development of TriLeukeVax, an Engineered Autologous Leukemia Vaccine for Stimulating Cytolytic Immune Responses to Residual Leukemic Stem Cells |
$6,000,000 |
| ImmunoVec |
Dr. Ryan L. Wong |
Late Stage Preclinical Projects |
Hematopoietic Stem Cell Gene Therapy for XCGD |
$3,999,959 |
| University of California, Los Angeles |
Dr. Antoni Ribas MD/PhD |
Late Stage Preclinical Projects |
Skin regeneration and wound healing with a topical BRAF inhibitor |
$5,005,126 |
| University of Southern California |
Dr. Denis A Evseenko Dr. |
Late Stage Preclinical Projects |
Plurocart: a novel stem cell-based implant for articular cartilage restoration |
$5,999,782 |
| University of California, San Diego |
Thomas J Kipps |
Late Stage Preclinical Projects |
Late Stage Pre-Clinical Development of a Cirmtuzumab Based CAR T-cell for the Treatment of ROR1+ Hematological Malignancies |
$1,630,360 |
| Stanford University |
Dr. Rosa Bacchetta |
Late Stage Preclinical Projects |
IND-enabling activities for a Phase 1 Study of Autologous CD4LVFOXP3 T Cells in Subjects with IPEX Syndrome |
$5,002,496 |
| University of California, San Francisco |
Mark C. Walters M.D. |
Late Stage Preclinical Projects |
Curing Sickle cell Disease with CRISPR-Cas9 genome editing |
$2,242,805 |
| University of California, Davis |
Dr. Diana L. Farmer |
Late Stage Preclinical Projects |
Placental Mesenchymal Stem Cell Augmentation of Fetal Myelomeningocele Repair |
$5,615,207 |
| Ankasa Regenerative Therapeutics, Inc. |
Ying Zhu |
Late Stage Preclinical Projects |
IND-enabling development of ART352-L, an endogenous stem cell reactivation therapy to enhance bone healing in the elderly |
$3,987,693 |
| City of Hope, Beckman Research Institute |
Xiuli Wang |
Late Stage Preclinical Projects |
CMV-specific T cells expressing anti-HIV CAR and CMV vaccine boost as immunotherapy for HIV/AIDS |
$3,812,797 |
| University of California, San Francisco |
Dr. Krystof Bankiewicz |
Late Stage Preclinical Projects |
MRI Guided Delivery of Neural Progenitor Cells Secreting GDNF for the Treatment of Parkinson’s disease |
$5,757,078 |
| Poseida Therapeutics, Inc. |
Devon J Shedlock |
Late Stage Preclinical Projects |
Late-Stage Preclinical Study of CAR-T Memory Stem Cells Targeting PSMA (P-PSMA-101) for the Treatment of Castrate-Resistant Metastatic Prostate Cancer |
$3,992,090 |
| City of Hope, Beckman Research Institute |
Dr. Angelo Manuel Almeida Cardoso Ph.D., MD |
Late Stage Preclinical Projects |
Ex Vivo Gene Engineering of Blood Stem Cells for Enhanced Chemotherapy Efficacy in Glioblastoma Patients |
$3,684,259 |
| University of California, Irvine |
Dr. Leslie M Thompson |
Late Stage Preclinical Projects |
An hESC-derived hNSC Therapeutic for Huntington’s Disease |
$5,635,393 |
| Fate Therapeutics, Inc. |
Bob Valamehr |
Late Stage Preclinical Projects |
IND enabling development of FT516: A Natural Killer Cell Immunotherapy for Cancer Derived from a Human Inducible Pluripotent Stem Cell |
$4,000,000 |
| Stanford University |
Dr. Matthew H Porteus |
Late Stage Preclinical Projects |
Genome Editing of Autologous Hematopoietic Stem Cells to Treat Sickle Cell Disease |
$4,849,363 |
| Cellerant Therapeutics, Inc. |
Swapna Panuganti |
Late Stage Preclinical Projects |
Development of CLT030-ADC, a Leukemic Stem Cell Targeting Antibody-Drug-Conjugate, for Treatment of Acute Myeloid Leukemia |
$6,863,755 |
| Cellular Biomedicine Group, Inc. |
Jack J. Wang |
Late Stage Preclinical Projects |
Allogenic human adipose-derived mesenchymal stem cells for the treatment of knee osteoarthritis |
$1,200,000 |
| Stanford University |
Dr. Gary Steinberg |
Late Stage Preclinical Projects |
Intraparenchymal NR1 Stem Cell Therapy for Chronic Subcortical Ischemic Stroke |
$5,300,000 |
| University of California, San Diego |
Dr. Stephanie Cherqui |
Late Stage Preclinical Projects |
Ex vivo transduced autologous human CD34+ hematopoietic stem cells for treatment of cystinosis |
$5,273,189 |
| University of California, Los Angeles |
Dr. Sophie X Deng |
Late Stage Preclinical Projects |
Regeneration of a Normal Corneal Surface by Limbal Stem Cell Therapy |
$4,244,211 |
| ViaCyte, Inc. |
Dr. Tim Kieffer |
Late Stage Preclinical Projects |
Stem cell-derived islet cell replacement therapy with immunosuppression for high-risk type 1 diabetes |
$3,544,721 |
| University of California, San Francisco |
Dr Jennifer M Puck |
Late Stage Preclinical Projects |
Ex Vivo Transduction of the Human Artemis (DCLRE1C) cDNA by Lentiviral Vector AProArt into CD34+ Hematopoietic Cells for Artemis (ART)-Deficient Severe Combined Immunodeficiency (SCID) |
$4,268,865 |
| Angiocrine Bioscience, Inc. |
Dr. Paul W Finnegan |
Late Stage Preclinical Projects |
Development of AB-110: genetically-modified endothelial cells plus expanded cord blood hematopoietic stem cells as a transplantation therapy |
$3,797,117 |
| Calibr |
Peter G Schultz |
Late Stage Preclinical Projects |
Development of a Chondrogenic Drug Candidate Targeting Resident Mesenchymal Stem Cells for the Treatment of Osteoarthritis |
$1,667,832 |
| Cedars-Sinai Medical Center |
Shaomei Wang |
Late Stage Preclinical Projects |
IND-enabling study of subretinal delivery of human neural progenitor cells for the treatment of retinitis pigmentosa |
$4,954,514 |
| Calibr |
Peter G Schultz |
Preclinical Development Awards |
Development of a Chondrogenic Drug Candidate Targeting Cartilage-residing Mesenchymal Stem Cells for the Treatment of Osteoarthritis |
$2,306,703 |
| Scripps Health |
Dr. Darryl D. D’Lima |
Preclinical Development Awards |
Embryonic Stem Cell-Derived Chondroprogenitor Cells to Repair Osteochondral Defects |
$7,660,211 |
| University of California, Davis |
Dr. Roslyn Rivkah Isseroff |
Preclinical Development Awards |
Scaffold for dermal regeneration containing pre-conditioned mesenchymal stem cells to heal chronic diabetic wounds |
$4,620,144 |
| University of California, Irvine |
Dr. Leslie M Thompson |
Preclinical Development Awards |
A hNSC Development Candidate for Huntington’s Disease |
$4,951,623 |
| Stanford University |
Dr. Matthew H Porteus |
Preclinical Development Awards |
Pre-clinical development of gene correction therapy of hematopoietic stem cells for SCID-X1 |
$874,877 |
| University of California, Davis |
Dr. Diana L. Farmer |
Preclinical Development Awards |
Placental Stem Cells for the In Utero Treatment of Spina Bifida |
$2,182,146 |
| Salk Institute for Biological Studies |
Dr. David R Schubert |
Preclinical Development Awards |
Human Stem-Cell Based Development of a Potent Alzheimer’s Drug Candidate |
$1,664,885 |
| ViaCyte, Inc. |
Howard Foyt |
Accelerated Development Pathway I |
Clinical Development of a Cell Therapy for Diabetes |
$8,783,852 |
| University of California, San Diego |
Catriona Jamieson |
Alpha Stem Cell Clinics |
Alpha Stem Cell Clinic for the Development of Regenerative Therapies |
$8,679,137 |
| University of California, Los Angeles |
John S. Adams |
Alpha Stem Cell Clinics |
UCLA-UCI Alpha Stem Cell Clinic (ASCC) Consortium |
$8,680,000 |
| City of Hope, Beckman Research Institute |
Prof. John A. Zaia |
Alpha Stem Cell Clinics |
The Innovation-Alpha Clinic for Cellular Therapies (I-ACT) – A Program for the Development and Delivery of Innovative Cell-based Treatments and Cures for Life-threatening Diseases. |
$8,416,531 |
| University of California, Davis |
Dr. J. Kent Leach |
Tools and Technologies III |
Multi-modal technology for non-destructive characterization of bioengineered tissues |
$1,574,151 |
